Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Vinci Concessions SAS and its subsidiary SunMind SAS in connection with its acquisition of Helios Nordic Energy AB from Magnora ASA, management and early investors
Mandate

Vinge advises Vinci Concessions SAS and its subsidiary SunMind SAS in connection with its acquisition of Helios Nordic Energy AB from Magnora ASA, management and early investors

May 30, 2024 M&A Employment and Benefits Environmental Law Real Estate and Construction Commercial Agreements Corporate Crime & Compliance EU, Competition and Regulatory Energy

Helios Nordic Energy specialises in developing solar farms and batteries to store energy until they become Ready to Build in the Nordics and Baltics.

The acquisition will enable SunMind to further enrich its expertise in renewable solar energy and other sources of renewable energy.

The current owners of Helios will receive an upfront payment of approximately EUR 73 million as well as a substantial earnout component tied to Helios's portfolio of unsold projects stretching over five years from closing.

The acquisition is subject to customary regulatory approvals.

Vinge's team primarily consisted of Peter Sundgren, Martin E Svanberg, Hanna Jansson and Fredrik Löwenclou (M&A), Amelia Rihs (Employment), Johan Cederblad and Lina Österberg (Environmental law), Kristoffer Larsson and Jasdeep Singh (Real Estate), Jolene Reimersson och Mario Saad (Commercial Agreements), Mia Falk (Compliance), David Olander and Lovisa Lewin (Regulatory),  Cecilia Loctander and  Caroline Löv (Transaction Support Coordinators).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026